Traws Pharma, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2024; filed May 15, 2024. The quarter’s financial statements reflect the pre-merger Onconova business and do not include Trawsfynydd Therapeutics, acquired April 1, 2024. The company subsequently changed its name to Traws Pharma and its Nasdaq ticker to TRAW.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $56,000 | $56,000 |
| Operating expenses | $5.268 million | $6.193 million |
| Operating loss | $5.212 million | $6.137 million |
| Other income, net | $229,000 | $362,000 |
| Net loss | $4.983 million | $5.775 million |
| Net loss per share | $0.24 | $0.28 |
| Net cash used in operations | $4.424 million | $4.543 million |
- Revenue came from recognition over time of a deferred upfront license payment under the SymBio collaboration. Revenue was unchanged year over year.
- Cash and cash equivalents were $16.390 million at March 31, down from $20.821 million at December 31, 2023. Total assets were $18.172 million; total liabilities were $12.157 million; stockholders’ equity was $6.015 million.
- Working capital was approximately $8.7 million. Current liabilities were $9.422 million, including $6.568 million of accounts payable. The balance sheet reports no interest-bearing debt.
- Operating expenses fell $925,000 year over year. General and administrative expense rose $1.243 million, mainly due to merger-related legal and professional fees; research and development expense fell $2.168 million, largely because of the timing of manufacturing and clinical-development costs. Lower interest income reflected reduced cash balances.
- Net cash decreased $4.431 million in Q1 2024. The filing reports no investing or financing cash flows for the quarter.
Merger, financing, and material changes
- On April 1, 2024, the company acquired Trawsfynydd and issued its former owners 3,549,538 common shares and 10,359.0916 Series C preferred shares. Each preferred share is convertible into 10,000 common shares, subject to stockholder approval and other terms. The company also assumed options exercisable for up to 454,000 common shares, subject to approval of the conversion proposals.
- At the merger closing, the company raised approximately $14 million gross in a private placement, issuing 496,935 common shares and 1,578.2120 Series C preferred shares. The financing proceeds were received after quarter-end and are not included in March 31 cash.
- Holders may elect cash redemption of Series C preferred shares if conversion approval is not obtained within six months after initial issuance; other redemption rights also apply under the preferred-stock terms. Potential redemptions could materially reduce available cash.
- Eligible common-stock holders, including merger recipients, were entitled to one contingent value right per share based on the April 15, 2024 record date. The CVRs provide for specified shares of net proceeds from a sale, license, transfer, or disposition of narazaciclib and rigosertib, or of net sales of those candidates, subject to contractual deductions.
- The company recorded approximately $1.7 million of merger transaction costs in Q1. Advisor compensation of approximately $1.0 million in cash, plus equity securities, was contingent on closing and is expected to be expensed in Q2. The company also estimated approximately $1.0 million of Q2 severance expense following its April 8 termination of 11 of 17 employees.
- Following the merger, the company plans to advance four clinical programs: influenza candidate viroxavir, COVID-19 candidate travatrelvir, cancer candidate narazaciclib, and rigosertib for epidermolysis bullosa-associated squamous cell carcinoma. The filing describes planned further viroxavir Phase 1 work before Phase 2 studies targeted for the second half of 2024; development timing and outcomes remain uncertain.
Liquidity, outlook, and risks
- Management states that cash, including the April private-placement proceeds, is expected to fund operations only into the fourth quarter of 2024. The company says it does not have sufficient resources to fund operations for at least 12 months after issuance of the financial statements and concludes that substantial doubt exists about its ability to continue as a going concern.
- The company expects continued operating losses and higher 2024 cash expenditures than in 2023, reflecting expanded clinical programs, merger costs, and acquired liabilities. It plans to seek additional dilutive and non-dilutive financing, including equity, alliances, and business-development transactions; there is no assurance funding will be available on acceptable terms.
- Key risks include clinical and regulatory uncertainty, dependence on third parties, integration and execution risks from the merger, dilution and possible preferred-stock cash redemptions, and the risk that further financing is unavailable. The company also reported failure to regain Nasdaq’s minimum bid-price requirement by March 25, 2024; it received an extension to September 23, 2024 and may need a reverse stock split. The filing warns of possible delisting if compliance is not regained.
- Management reported disclosure controls and procedures were effective as of March 31, 2024 and no material change in internal control over financial reporting during the quarter. The company reported no pending material legal proceedings.
Important facts for investors to verify
- Current cash balance and projected runway after merger-related, severance, and clinical-development spending; the filing’s going-concern conclusion remains material despite the $14 million financing.
- Stockholder approval timing and outcome for Series C conversion, the number of shares ultimately issued, and any cash-redemption exposure.
- Nasdaq bid-price compliance progress and whether a reverse stock split or other action is required.
- Clinical-trial milestones, enrollment, results, regulatory interactions, and actual development timelines for the acquired and legacy programs.
- Merger integration costs, workforce-reduction effects, and any future financing, partnership, or asset-monetization terms.